Two very different categories, one confusing shelf of names
If you've spent any time researching recovery peptides, you've probably seen names like BPC-157, TB-500, copper peptide, Pentadeca Arginate, and SLU-PP-332 mentioned in the same breath, as if they were interchangeable options on a menu. They aren't. Some of these are preclinical research compounds studied mainly in lab and animal models. Others carry a different status that involves individual clinician review before any personal conclusion is possible. Knowing which category a compound falls into is the first real step in doing useful research, and it will make any consultation conversation far more productive.
research-stage compounds: education, not treatment
Explore the current research, note where questions remain, and bring those questions to a consultation alongside established options. That means the available evidence largely comes from laboratory and animal studies, not established human clinical use. These compounds are best discussed in a consultation alongside established options, and no outcome, safety profile, or timeline should be assumed from what you read online. If a compound is in this category, the most useful thing you can do is understand the general mechanism being studied and recognize that translating early research into a personal treatment decision is not something general information can do for you.
Clinician-review peptides: a different starting point
Copper peptide (GHK-Cu) sits in a separate category. It is discussed as a topic that requires individual clinician review, meaning questions about route, formulation, and whether it could be relevant to you depend on a conversation with a provider rather than general reading. This distinction matters because clinician review is about individual suitability, not a shortcut past questions of availability, formulation, or program fulfillment. Understanding this difference before you reach out helps you ask sharper questions instead of assuming any topic is automatically available or appropriate.
Questions worth preparing before you reach out
Before requesting a consultation, it can help to write down what you actually want to know: Which category does the compound I'm curious about fall into? What has research actually shown, and what has it not shown? What would a clinician need to know about my health history to have a useful conversation? Are there safety considerations I should understand regardless of category? Bringing specific questions like these, rather than a general request for a product, tends to lead to a more useful first conversation.
What a consultation can and cannot do
A consultation request lets our team follow up and talk through your questions; it is not a checkout process, and submitting the form does not create a treatment plan on its own. If a topic requires individual clinician review, that review addresses whether the topic may be relevant to you personally. It does not, by itself, confirm formulation, program availability, testing requirements, or fulfillment. Those are separate questions that depend on verified program details discussed directly with the care team.
Frequently asked questions
See the FAQ section below for answers to common questions about research-stage compounds, clinician-review peptides, testing, and what happens after you request a consultation.
Ready to ask your questions?
Have questions about a specific peptide or recovery topic? Request a consultation and our team will follow up to talk through what you want to know.
Request a consultation
Have questions about a specific peptide or recovery topic? Request a consultation and our team will follow up to talk through what you want to know.
FAQs
Are BPC-157, TB-500, and similar peptides available as treatments through this site?
No. Explore the current research, note where questions remain, and bring those questions to a consultation alongside established options. Bring questions about current research and established options to a consultation; the team can clarify availability and what may be relevant to your situation.
What's the difference between a research-stage compound and a clinician-review compound?
research-stage compounds like BPC-157 or TB-500 are discussed based on lab and animal research, with no treatment claim implied. Clinician-review compounds, like copper peptide, require an individual conversation with a provider about route, formulation, and personal relevance before any conclusion can be drawn.
Do I need blood work before discussing peptide topics in a consultation?
Whether any testing is relevant depends on your individual situation and what a clinician determines during review. We can't say in advance that the same labs apply to every reader.
Is telehealth available for this topic?
Availability depends on verified program details that a member of the care team can walk you through after you request a consultation.
I'm already using a related peptide from another provider. Can I still ask questions here?
Yes. You're welcome to request a consultation to ask about your current approach and any questions you have; the team will follow up using the contact details you provide.
Does requesting a consultation mean I'll automatically be offered a specific peptide?
No. A consultation is a chance to ask questions and discuss individual fit. It does not guarantee eligibility, availability, or that any specific compound will be part of your next steps.
Why does this page separate research compounds from clinician-review peptides instead of listing them together?
Because they carry genuinely different evidence bases and review requirements. Keeping them distinct helps you ask accurate questions instead of assuming every peptide on the page works the same way.